| Document |
Document Title |
|
WO/2013/182423A1 |
The invention relates to dronedarone or one of its pharmaceutically acceptable salts for the treatment of leishmaniasis, formulations and associations comprising dronedarone or one of its pharmaceutically acceptable salts for the treatme...
|
|
WO/2013/184006A1 |
This invention relates to a method of treating a non-human animal infested with biting lice characterised by the step of administering internally to the animal a pharmaceutically effective amount of neonicotinoid such that the neonicotin...
|
|
WO/2013/180193A1 |
A compound represented by formula (1) and an N-oxide thereof have excellent pest control effect. (In the formula, Het to which R1-S(O)n is bonded represents a five-membered aromatic heterocyclic ring represented by formula H1, H2, H3 or ...
|
|
WO/2013/177978A1 |
The present invention belongs to the field of pharmaceutical chemicals, and relates to a pegylated artesunate derivative, pharmaceutical composition and use thereof. In particular, the present invention relates to a pegylated artesunate ...
|
|
WO/2013/180194A1 |
This fused heterocyclic compound represented by formula (1) (in the formula, G1 represents a nitrogen atom or the like, G2 represents a nitrogen atom or the like, A1 represents a nitrogen atom or the like, A2 represents a nitrogen atom o...
|
|
WO/2013/174645A1 |
The present invention relates to N-thioanthranilamide compounds of formula (I), and the stereoisomers, N-oxides and agriculturally or veterinarily acceptable salts thereof, wherein the substituents are as defined in the description. The ...
|
|
WO/2013/170656A1 |
Disclosed are fluoroethyl thiamine or its salt and application thereof in preparing anticoccidial drugs. A structural formula of the fluoroethyl thiamine or its salt is shown in formula (1). The fluoroethyl thiamine or its salt of the pr...
|
|
WO/2013/171159A1 |
The present invention relates to a topical pharmaceutical composition comprising, based on the total weight of the composition: a) from 1.5 wt. % to 5 wt. % of terbinafine or any pharmaceutically acceptable salt thereof; b) from 15 wt. %...
|
|
WO/2013/167295A1 |
(R)-Nifuratel is disclosed together with its use as bactericide and bacteriostatic agent as well as the pharmaceutical compositions containing the same; (R)- nifuratel has been surprisingly found to possess a better antimicrobial profile...
|
|
WO/2013/167640A1 |
The present invention concerns the use of lufenuron for controlling sea lice in a fish population, which comprises feeding lufenuron to the fish population according to a specific regime as outlined in the specification and claims. The p...
|
|
WO/2013/166576A1 |
The present invention describes the method for producing the dichloromethane fraction and subfractions of Eleutherine plicata, commonly known as "marupazinho, maruparí, palmeirinha, coquinho, marupaí, marupaú, marupá-piranga, lírio-...
|
|
WO/2013/163734A1 |
The present application realtes to non-aqueous topical pharmaceutical formulations that are non-desquamating. The formulation comprises an organic solvent with tisssue-permeation properties, an organic co-solvent and a film forming agent...
|
|
WO/2013/158422A1 |
Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein R2, R4, R5, R6, A, L, Q and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling ...
|
|
WO/2013/158628A1 |
The present invention is directed to a composition for the treatment or prevention of cerebral malaria that comprises an angiotensin receptor type-2 agonist and an antimalaria drug. The present invention is further directed to methods fo...
|
|
WO/2013/154080A1 |
The present invention provides: an aryloxyurea compound which can be industrially advantageously synthesized, while having excellent acaricidal activity and/or insecticidal activity and excellent safety, or a salt thereof; and a pest con...
|
|
WO/2013/154016A1 |
The present invention provides an ophthalmic composition comprising (A) a biguanide-type bactericidal agent and (B) zinc chloride. The present invention can provide an ophthalmic composition having a significantly improved disinfecting e...
|
|
WO/2013/154209A1 |
The present invention relates to an antiprotozoan composition containing caspofungin or its salt and a biguanide compound or its salt.
|
|
WO/2013/153357A1 |
The present invention relates to a novel class of quinolone-4-carboxamide Pf3D7 inhibitors of general formula (I) (Formula (I)) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and in the trea...
|
|
WO/2013/149903A1 |
The invention relates to N-substituted hetero-bicyclic furanone compounds of formula (I), to the enantiomers, diastereomers and salts thereof and to compositions comprising such compounds. The invention also relates to methods and uses o...
|
|
WO/2013/150140A1 |
The invention relates to new phenanthroline derivatives of the general formulae (I), (II), (III) or (IV) as a drug for treating cancer or a disease selected from the group consisting of microbial, fungal, viral and/or inflammatory diseas...
|
|
WO/2013/149800A1 |
The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also rela...
|
|
WO/2013/148857A1 |
A compound of structural formula (I) or (II): as HSP90 inhibitors that possess significantly improved bioavailability over comparative compounds, which are suitable for the treatment of hyperproliferative diseases such as cancer, infecti...
|
|
WO/2013/144179A1 |
This invention relates to certain heteroaryl compounds which may be used as medicaments, more specifically as medicaments for treating animals. The medicament can be used for the treatment of parasitic infections such as helminth infecti...
|
|
WO/2013/142278A1 |
The invention provides P. vivax vaccine compositions.
|
|
WO/2013/137371A1 |
A medicine which can decrease an LDL level in blood and comprises, as an active ingredient, a compound represented by general formula (I) (wherein R1 represents a hydrogen atom or a group represented by formula (II) (wherein R3 represent...
|
|
WO/2013/135571A1 |
An antibiotic composition comprising miltefosine and polyhexamethylene biguanide (PHMB) and its use in the prevention or treatment of a condition of the eye or the skin is provided by the present invention.
|
|
WO/2013/137748A1 |
The present invention relates to a long-acting composition for the treatment of an animal in need thereof wherein the composition includes a therapeutically effective amount of a bioactive agent, characterised in that the composition inc...
|
|
WO/2013/131164A1 |
The present invention relates to a pharmaceutical composition for treating visceral leishmaniasis, characterized in that it comprises the association of conventional liposomes and prolonged-circulation liposomes with a leishmanicidal-dru...
|
|
WO/2013/128425A1 |
The subject matter of the present invention is compounds of formula (I), processes for preparing same, and also uses thereof in the therapeutic field and in the materials field.
|
|
WO/2013/127981A1 |
Disclosed is the use of protease inhibitors for use in the treatment of a Trichomonas gallinae infection of an animal, selected from the orders Galliformes, Passeriformes, Psittaciformes, Columbiformes and Falconiformes.
|
|
WO/2013/126694A1 |
The subject matter disclosed herein is directed to stable, highly-effective topical formulations comprising permethrin, fipronil and a solvent system that is sufficient to solubilize these two active ingredients and limit degradation of ...
|
|
WO/2013/124025A1 |
Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus
|
|
WO/2013/124441A1 |
This invention concerns the use of a compound dialkyl-thiosulfinate and/or a compound dialkyl-thiosulfonate to improve the disease resistance of an animal infected by a pathogen. The pathogen may be a virus, bacteria or apicomplexa. The ...
|
|
WO/2013/123412A1 |
This invention relates to compositions and methods for eliciting an immune response against a parasite of the genus Plasmodium in a mammal.
|
|
WO/2013/122041A1 |
The invention provides an aryloxyacetamide compound represented by a formula such as formula (IV) (in formula (IV), R1a is an alkyl group or the like, R2-R5 are each independently an alkyl group or the like, X is a halogen atom or the li...
|
|
WO/2013/121387A1 |
The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the prep...
|
|
WO/2013/118858A1 |
It is achieved successfully to obtain a polypeptide having improved stability compared with that of a parent polypeptide thereof by modifying at least one amino acid residue located in a loop domain in an Fc region of an antibody. In add...
|
|
WO/2013/119442A1 |
This invention relates to oral veterinary compositions for combating ectoparasites and endoparasites in animals, comprising at least one systemically-acting active agent in combination with a pharmaceutically acceptable carrier. This inv...
|
|
WO/2013/118606A1 |
Provided is a drug for preventing or treating malaria, the drug containing an effective amount of a compound that lowers the blood concentration of α-tocopherol.
|
|
WO/2013/115391A1 |
An arylalkyloxy pyrimidine derivative represented by general formula (I) or a salt thereof; a pesticide for agricultural and horticultural use, which contains the compound as an active ingredient; and a use of the pesticide for agricultu...
|
|
WO/2013/113102A1 |
As described herein, there is provided methods for identifying a subject with an increased likelihood of developing or having metastatic papillary thyroid cancer (PTC), or a subject with an increased likelihood of developing or having re...
|
|
WO/2013/110975A1 |
The invention relates to an orally administered pharmaceutical nitazoxanide composition used for the treatment of intestinal parasitic infections, in the form of granules for suspension, in which said composition contains: (a) an immedia...
|
|
WO/2013/110830A1 |
The invention relates to a pharmaceutical composition comprising isometamidium chloride with a concentration of 1 % to 4 % (weight/volume), isopropylidene glycerol or glycerine formal with a concentration of 40 % to 95 % (weight/volume),...
|
|
WO/2013/109866A1 |
The present invention provides methods for chemically synthesizing naturally- occuring alkaloids, for example, Flindersia alkaloids, and their analogs and derivatives. Generally, the precursor borrerine is synthesized from tryptamine in ...
|
|
WO/2013/106847A1 |
Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as...
|
|
WO/2013/106592A1 |
A miR-196a antagonist capable of inhibiting a miR-196a activity, the miR-196a antagonist comprising one or more target sites for miR-196a. Included is also an expression vector comprising a promoter and a nucleic acid insert operably lin...
|
|
WO/2013/095276A1 |
The present invention relates to a chemically modified heparin, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Als...
|
|
WO/2013/092942A1 |
The present invention relates to a pharmaceutical composition comprising at least one aminobenzamide derivative or a salt thereof for preventing infection with diseases transmitted through parasites and controlling of parasites on and in...
|
|
WO/2013/096512A1 |
Methods of treating gastrointestinal disorders, in a patient in need thereof, including disorders of the liver and pancreas, using an amount of an orally dosed TLR-7 compound in an amount sufficient to increase IFN in the gastrointestina...
|
|
WO/2013/092868A1 |
The present invention relates to N-thio-anthranilamide compounds of the formula (I), the stereoisomers, the salts, the tautomers and the N-oxides thereof, wherein R1 is hydrogen, C1-C6-alkyl or C3-C8-cycloalkyl; R2 is hydrogen, halogen o...
|
